Objective. To study the interaction of interleukin-la (IL-la) and oncostatin M (OSM) in promoting cartilage collagen destruction.Methods. Bovine, porcine, and human cartilage and human chondrocytes were studied in culture. The levels of collagenase (matrix metalloproteinase 1 [MMP-I]) and tissue inhibitor of metalloproteinases 1 (WMP-1) were measured by bioassay and enzyme-linked immunosorbent assay (ELISA). The levels of OSM in rheumatoid synovial fluid were measured by ELISA.Results. When combined with OSM, 1L-la, ILlp, and tumor necrosis factor a released proteoglycan and collagen from cartilage. OSM was the only member of the IL-6 family to have this effect. Human tendon also responded to IL-la and OSM. OSM increased the production of MMP-1 and TIMP-1 but when combined with IL-la, synergistically promoted MMP-1 production in human chondrocytes and synovial fibroblasts. High levels of OSM were found in human rheumatoid synovial fluids, and confocal microscopy showed that OSM was produced by macmphages in rheumatoid synovial tissue. Conclusion. These results highlight an important

Objective: To investigate whether interleukin 17 (IL17), derived specifically from T cells, can promote type II collagen release from cartilage. The ability of IL17 to synergise with other proinflammatory mediators to induce collagen release from cartilage, and what effect anti-inflammatory agents had on this process, was also assessed. Methods: IL17 alone, or in combination with IL1, IL6, oncostatin M (OSM), or tumour necrosis factor α (TNFα), was added to bovine nasal cartilage explant cultures. Proteoglycan and collagen release were determined. Collagenolytic activity was determined by bioassay. Chondroprotective effects of IL4, IL13, transforming growth factor β1 (TGFβ1) and insulin-like growth factor-1 (IGF1) were assessed by inclusion in the explant cultures. Results: IL17 alone stimulated a dose dependent release of proteoglycan and type II collagen from bovine nasal cartilage explants. Suboptimal doses of IL17 synergised potently with TNFα, IL1, OSM, and IL6 to promote collagen degradation. This collagen release was completely inhibited by tissue inhibitor of metalloproteinase-1 and BB-94 (a synthetic metalloproteinase inhibitor), and was significantly reduced by IL4, IL13, TGFβ1, and IGF1. In IL17 treated chondrocytes, mRNA expression for matrix metalloproteinase (MMP)-1, MMP-3, and MMP-13 was detected. Moreover, a synergistic induction of these MMPs was seen when IL17 was combined with other proinflammatory cytokines. Conclusions: IL17 can, alone and synergistically in combination with other proinflammatory cytokines, promote chondrocyte mediated MMP dependent type II collagen release from cartilage. Because levels of all these proinflammatory cytokines are raised in rheumatoid synovial fluids, this study suggests that IL17 may act as a potent upstream mediator of cartilage collagen breakdown in inflammatory joint diseases.

Articular cartilage is a highly specialized tissue that covers the surface of synovial joints, allowing its smooth articulation. Cartilage is synthesized and maintained by chondrocytes, and is composed primarily of water, proteoglycan (principally aggrecan), and collagen (1). Type II collagen fibrils are arranged to form a fibrillar network within which are trapped aggrecan molecules that pull water into the tissue. These two components provide cartilage with its tensile strength and the ability to resist compression. The degradation of cartilage is one of the key features of the arthritides and results in disability.The degradation of cartilage in vitro and in vivo is believed to be mediated by neutral endopeptidases of the metalloproteinase class of enzymes (2). Two families in this class that have been implicated are the matrix metalloproteinase (MMP) and ADAM families (2,3).

No abstract

No abstract